Oncotarget

Research Papers:

This article has been corrected. Correction in: Oncotarget. 2018; 9:34190.

Cytochrome P450 1B1 inhibition suppresses tumorigenicity of prostate cancer via caspase-1 activation

Inik Chang _, Yozo Mitsui, Seul Ki Kim, Ji Su Sun, Hye Sook Jeon, Jung Yun Kang, Nam Ju Kang, Shinichiro Fukuhara, Ankurpreet Gill, Varahram Shahryari, Z. Laura Tabatabai, Kirsten L. Greene, Rajvir Dahiya, Dong Min Shin and Yuichiro Tanaka

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:39087-39100. https://doi.org/10.18632/oncotarget.16598

Metrics: PDF 1221 views  |   HTML 1430 views  |   ?  


Abstract

Inik Chang1,*, Yozo Mitsui2,3,*, Seul Ki Kim1,4, Ji Su Sun1,4, Hye Sook Jeon1, Jung Yun Kang1,4, Nam Ju Kang1,4, Shinichiro Fukuhara2,3, Ankurpreet Gill2, Varahram Shahryari2, Z. Laura Tabatabai5, Kirsten L. Greene5, Rajvir Dahiya2,3, Dong Min Shin1,4 and Yuichiro Tanaka2,3

1Department of Oral Biology, Yonsei University College of Dentistry, Seoul, South Korea

2Department of Surgery and Division of Urology, Veterans Affairs Medical Center, San Francisco, California, United States of America

3Department of Urology, University of California, San Francisco, California, United States of America

4BK21 PLUS Project, Yonsei University College of Dentistry, Seoul, South Korea

5Department of Pathology, Veterans Affairs Medical Center and University of California, San Francisco, California, United States of America

*These authors have contributed equally to this work

Correspondence to:

Inik Chang, email: ichang@yuhs.ac

Yuichiro Tanaka, email: yuichiro.tanaka@ucsf.edu

Keywords: CYP1B1, prostate cancer, tumorigenicity, shRNA, caspase-1

Received: December 29, 2016     Accepted: March 01, 2017     Published: September 25, 2018

ABSTRACT

Cytochrome P450 1B1 (CYP1B1) is recognized as a universal tumor biomarker and a feasible therapeutic target due to its specific overexpression in cancer tissues. Despite its up-regulation in prostate cancer (PCa), biological significance and clinicopathological features of CYP1B1 are still elusive. Here, we show that overexpression or hyperactivation of CYP1B1 stimulated proliferative, migratory and invasive potential of non-tumorigenic PCa cells. Attenuation of CYP1B1 with its specific small hairpin (sh) RNAs greatly reduced proliferation through apoptotic cell death and impaired migration and invasion in PCa cells. Intratumoral injection of CYP1B1 shRNA attenuated growth of pre-existing tumors. The antitumor effect of CYP1B1 shRNA was also observed in prostate tumor xenograft mouse models. Among the genes altered by CYP1B1 knockdown, reduction of caspase-1 (CASP1) activity attenuated the antitumor effect of CYP1B1 inhibition. Indeed, CYP1B1 regulates CASP1 expression or activity. Finally, CYP1B1 expression was increased in higher grades of PCa and overall survival was significantly reduced in patients with high levels of CYP1B1 protein. CYP1B1 expression was reversely associated with CASP1 expression in clinical tissue samples. Together, our results demonstrate that CYP1B1 regulates PCa tumorigenesis by inhibiting CASP1 activation. Thus, the CYP1B1-CASP1 axis may be useful as a potential biomarker and a therapeutic target for PCa.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16598